Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules

Human and Experimental Toxicology

Volumn 19, Issue 11, 2000, Pages 615-622

  Teo, S ^a  

^a NONE   (United States)

Author keywords

Chronic administration; Distal spinal cord; Dogs; Histologic ultrastructural evaluation; Peripheral neuropathy; Sensory nerve action potential; Sensory nerve conduction velocity; Sural nerve; Thalidomide

Indexed keywords

THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG CAPSULE; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; MALE; NERVE FUNCTION; NERVE POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION; SURAL NERVE; TIBIAL NERVE; ULTRASTRUCTURE;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ANIMALS; CAPSULES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVOKED POTENTIALS, SOMATOSENSORY; FEMALE; LEPROSTATIC AGENTS; MALE; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; SURAL NERVE; THALIDOMIDE; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0034492020     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032700673027800     Document Type: Article

References (6)

1. Calabrese L. Thalidomide's tightly controlled "comeback." Cleveland Clin J Med 1999; 66: 136-138.
2. Sheskin J. Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther 1965; 6: 303-300.
3. Jacobson JM, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis 1999; 180: 61-67.
4. Eisen T, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 1999; 82: 812-817.
5. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997; 350: 1445-1446.
6. Tracey K, et al. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 1988; 167: 1211-1227.